

Your membership matters.

Continue to help lead the fight against kidney disease. Renew today.

www.asn-online.org/membership



CJASN

Clinical Journal of the
American Society of Nephrology

[HOME](#) | [CURRENT ISSUE](#) | [ADVERTISE](#) | [SUBSCRIBE](#) | [ARCHIVES](#) | [FEEDBACK](#) | [ALERTS](#) | [HELP](#)

Two phosphATe tarGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial

Ron Wald*, †, Christian G. Rabbat‡, Louis Girard§, Amit X. Garg||, Karthik Tennankore¶, Jessica Tyrwhitt**, Andrew Smyth**, Andrea Rathe-Skafel*, Peggy Gao**, Andrea Mazzetti**, Jackie Bosch**, Andrew T. Yan†, ‡, Patrick Parfrey‡‡, Braden J. Manns§, §§, Michael Walsh‡, **

[+ Author Affiliations](#)

Correspondence:

Dr. Ron Wald, Division of Nephrology, St. Michael's Hospital, Scientist, Li Ka Shing 61 Queen Street East, 9-140, Toronto, ON M5C 2T2. Email: waldr@smh.ca

Abstract

Background and objectives Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial.

Design, setting, participants, & measurements We conducted a randomized controlled trial of prevalent hemodialysis recipients already receiving calcium carbonate as a phosphate binder at five Canadian centers between March 31, 2014 and October 2, 2014. Participants were randomly allocated to 26 weeks of an intensive phosphate goal of 2.33–4.66 mg/dl (0.75–1.50 mmol/L) or a liberalized target of 6.20–7.75 mg/dl (2.00–2.50 mmol/L) by titrating calcium carbonate using a dosing nomogram. The primary outcome was the difference in the change in serum phosphate from randomization to 26 weeks.

Results Fifty-three participants were randomized to the intensive group and 51 to the liberalized group. The median (interquartile range) daily dose of elemental calcium at 26 weeks was 1800 (1275–3000) mg in the intensive group, and 0 (0–500) mg in the liberalized group. The mean (SD) serum phosphate at 26 weeks was 4.53 (1.12) mg/dl (1.46 [0.36] mmol/L) in the intensive group and 6.05 (1.40) mg/dl (1.95 [0.45] mmol/L) in the liberalized group. Phosphate concentration in the intensive group declined by 1.24 (95% confidence interval, 0.75 to 1.74) mg/dl (0.40 [95% confidence interval, 0.24 to 0.56] mmol/L) compared with the liberalized group. There were no statistically significant differences between the two groups in the risk of hypercalcemia, hypocalcemia, parathyroidectomy, or major vascular events.

Conclusions It is feasible to achieve and maintain a difference in serum phosphate concentrations in hemodialysis recipients by titrating calcium carbonate. A large trial is needed to determine if targeting a lower serum phosphate concentration improves patient-important outcomes.

Hemodialysis phosphate binders randomized controlled trials
Calcium Carbonate Calcium, Dietary Canada Goals Humans
Hypercalcemia hyperphosphatemia Hypocalcemia
Kidney Failure, Chronic Nomograms Parathyroidectomy Phosphates
Pilots Prevalence Random Allocation renal dialysis
renal insufficiency, chronic

Received October 20, 2016.

Accepted February 15, 2017.

[« Previous](#) | [Next Article »](#)
[Table of Contents](#)

This Article

Published online before print May 2017, doi: 10.2215/CJN.10941016
CJASN June 07, 2017 vol. 12 no. 6 965–973

» Abstract Free

Figures Only

[Full Text](#)

[Full Text \(PDF\)](#)

Supplemental Data

Article Usage Stats

Article Usage Statistics



Services

Email this article to a colleague

Alert me when this article is cited

Alert me if a correction is posted

Similar articles in this journal

Similar articles in PubMed

Download to citation manager

[Get Permissions](#)

Citing Articles

[Google Scholar](#)

[PubMed](#)

[Related Content](#)

User Name
 User Name
Password

Search
[Advanced Search](#)

Current Issue
March 07, 2018, 13 (3)



Alert me to new issues of CJASN

ONLINE SUBMISSION

AUTHOR RESOURCES

ABOUT CJASN

EDITORIAL BOARD

REPRINTS / PERMISSIONS

IMPACT FACTOR

MOST READ

MOST CITED

CJASN ePress

Updated on:
March 9, 2018
By Date / By Subject



[Advertising Disclaimer](#)

Related articles

Editorials:

Robert E. Olivo and Julia J. Scialla

Getting Out of the Phosphate Bind: Trials to Guide Treatment Targets

CJASN June 07, 2017 12): (6) 868–870; published ahead of print May 26, 2017, doi:10.2215/CJN.04380417

[»Full Text](#) [»Full Text \(PDF\)](#)

We recommend

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial

Andrea Rathe-Skafel et al., Clin J Am Soc Nephrol

Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

Christopher W McIntyre et al., Clin J Am Soc Nephrol

Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.

Rajnish Mehrotra et al., Clin J Am Soc Nephrol

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Stuart M Sprague et al., Clin J Am Soc Nephrol

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.

John T Daugirdas et al., J Am Soc Nephrol

Evaluation of responses to vitamin D3 (cholecalciferol) in patients on dialysis: a systematic review and meta-analysis 

Chen Xu et al., J Investig Med

Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis 

Connie C W Hsia et al., J Investig Med

Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis 

Annemarie B Docherty et al., The BMJ

Case Study: Tea-Colored Urine in a Patient With Diabetic Ketoacidosis 

Hylton V. Joffe et al., Clin Diabetes

Automatic insulin pump suspension reduces hypoglycemia in adolescents with diabetes 

Medicine Matters diabetes

Powered by 

Be a part of something innovative, influential and dynamic.

Be a part of ASN.



ASN members enjoy discounts on ASN's educational programs, subscriptions to ASN's publications, and more.

Join or renew today at www.asn-online.org/membership

